Research ArticleArticle
Cost-Effectiveness of Combination Nonbiologic Disease-Modifying Antirheumatic Drug Strategies in Patients with Early Rheumatoid Arthritis
JONATHAN C. TOSH, ALLAN J. WAILOO, DAVID L. SCOTT and CHRIS M. DEIGHTON
The Journal of Rheumatology August 2011, 38 (8) 1593-1600; DOI: https://doi.org/10.3899/jrheum.101327
JONATHAN C. TOSH
ALLAN J. WAILOO
DAVID L. SCOTT
REFERENCES
- 1.↵
- Symmons D,
- Turner G,
- Webb R,
- Asten P,
- Barrett E,
- Lunt M,
- et al.
- 2.↵
- Cooper NJ
- 3.↵
- 4.↵National Institute for Health and Clinical Excellence. TA130 — Rheumatoid arthritis: adalimumab, etanercept and infliximab. [Internet. Accessed March 16, 2011.] Available from: http://guidance.nice.org.uk/TA130
- 5.↵
- Goekoop-Ruiterman YP,
- de Vries-Bouwstra JK,
- Allaart CF,
- van Zeben D,
- Kerstens PJ,
- Hazes JM,
- et al.
- 6.↵
- 7.↵
- Hetland ML,
- Stengaard-Pedersen K,
- Junker P,
- Lottenburger T,
- Ellingsen T,
- Andersen LS,
- et al.
- 8.↵
- Jobanputra P,
- Wilson J,
- Douglas K,
- Burls A
- 9.↵
- Emery P
- 10.↵
- 11.↵
- Verhoeven AC,
- Bibo JC,
- Boers M,
- Engel GL,
- van der Linden S
- 12.↵
- Korthals-de Bos I,
- Van Tulder M,
- Boers M,
- Verhoeven AC,
- Ader HJ,
- Bibo J,
- et al.
- 13.↵
- Brennan A,
- Bansback N,
- Nixon R,
- Madan J,
- Harrison M,
- Watson K,
- et al.
- 14.↵National Institute for Health and Clinical Excellence. Rheumatoid arthritis: national guideline for the management and treatment in adults. London: Royal College of Physicians; 2009.
- 15.↵World Health Organization. Technology appraisal programme of the National Institute of Clinical Excellence. A review by WHO. Geneva: World Health Organization; 2003.
- 16.↵
- 17.↵
- Dougados M,
- Combe B,
- Cantagrel A,
- Goupille P,
- Olive P,
- Schattenkirchner M,
- et al.
- 18.↵
- Gerards AH,
- Landewe RB,
- Prins AP,
- Bruyn GA,
- Goei Thé HS,
- Laan RF
- 19.↵
- Proudman SM,
- Conaghan PG,
- Richardson C,
- Griffiths B,
- Green MJ,
- McGonagle D,
- et al.
- 20.↵
- Miranda JM,
- Avarez-Nemegyei J,
- Saavedra MA,
- Teran L,
- Galvan-Villegas F,
- Figueroa J,
- et al.
- 21.↵
- Sarzi-Puttini P,
- D’Ingianna E,
- Fumagalli M,
- Scarpellini M,
- Fiorini T,
- Cherie-Ligniere EL,
- et al.
- 22.↵
- Marchesoni A,
- Battafarano N,
- Arreghini M,
- Panni B,
- Gallazzi M,
- Tosi S
- 23.↵
- Van den Borne B,
- Landewe RB,
- Goei Thé HS,
- Rietveld JH,
- Zwinderman AH,
- Bruyn GA,
- et al.
- 24.↵
- 25.↵
- Capell HA,
- Madhok R,
- Hunter JA,
- Porter D,
- Morrison E,
- Larkin J,
- et al.
- 26.↵
- 27.↵
- 28.↵
- 29.↵
- Caldwell DM,
- Ades AE,
- Higgins JP
- 30.↵
- 31.↵
- Spiegelhalter D,
- Thomas A,
- Best N,
- Lunn D
- 32.↵Bristol-Myers Squibb. Abatacept for the treatment of rheumatoid arthritis — manufacturer’s submission for NICE TA141. 2008.
- 33.↵
- Bansback NJ,
- Brennan A,
- Ghatnekar O
- 34.↵
- Hurst NP,
- Kind P,
- Ruta D,
- Hunter M,
- Stubbings A
- 35.↵
- 36.↵
- 37.↵National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (2008 Updated). [Internet. Accessed March 16, 2011.] Available from: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf
- 38.↵
- 39.↵
- Saraux A,
- Berthelot JM,
- Chalès G,
- Le Henaff C,
- Thorel JB,
- Hoang S,
- et al.
- 40.↵
- 41.↵
- Combe B,
- Landewe R,
- Lukas C,
- Bolosiu HD,
- Breedveld F,
- Dougados M,
- et al.
In this issue
The Journal of Rheumatology
Vol. 38, Issue 8
1 Aug 2011
Cost-Effectiveness of Combination Nonbiologic Disease-Modifying Antirheumatic Drug Strategies in Patients with Early Rheumatoid Arthritis
JONATHAN C. TOSH, ALLAN J. WAILOO, DAVID L. SCOTT, CHRIS M. DEIGHTON
The Journal of Rheumatology Aug 2011, 38 (8) 1593-1600; DOI: 10.3899/jrheum.101327